Trademarkia Logo

Canada

C$
VOGEVMA
SEARCHED

on 4 Feb 2025

Last Applicant/ Owned by

Teva Pharmaceuticals USA, Inc.

400 Interpace ParkwayBuilding AParsippany, NJ 07054

US

Serial Number

2216539 filed on 19th Oct 2022

Correspondent Address

OSLER, HOSKIN & HARCOURT LLP

Suite 320, World Exchange Plaza100 Queen StreetOttawa,

ONTARIO

CA

K1P1J9

VOGEVMA

Trademark usage description

pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, card Read More

Classification Information


Class [005]
Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders (skin), musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for use in the treatment of oncological and metabolic diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations.


Classification kind code

11

Mark Details


Serial Number

2216539

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 22
on 4th Feb 2025
Search Recorded
Submitted for opposition 20
on 4th Feb 2025
Examiner's First Report
Submitted for opposition 287
on 27th Oct 2022
Pre-Assessment Letter Sent
Submitted for opposition 30
on 19th Oct 2022
Filed
Submitted for opposition 1
on 19th Oct 2022
Created
Submitted for opposition 31
on 19th Oct 2022
Formalized